{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:15:14Z","timestamp":1781846114147,"version":"3.54.5"},"reference-count":34,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T00:00:00Z","timestamp":1545868800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T00:00:00Z","timestamp":1545868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100012986","name":"Universidad Francisco de Vitoria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012986","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Neurol Scand"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1111\/ane.13059","type":"journal-article","created":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T12:49:01Z","timestamp":1543668541000},"page":"360-368","source":"Crossref","is-referenced-by-count":78,"title":["BRIVA-LIFE-A multicenter retrospective study of the long-term use of brivaracetam in clinical practice"],"prefix":"10.1155","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2080-8042","authenticated-orcid":false,"given":"Vicente","family":"Villanueva","sequence":"first","affiliation":[{"name":"La Fe University Hospital and Polytechnic; Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"L\u00f3pez-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Clinical University Hospital; Santiago Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Angel","family":"Mauri","sequence":"additional","affiliation":[{"name":"Lozano Blesa University Hospital; Zaragoza Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Rodriguez-Uranga","sequence":"additional","affiliation":[{"name":"Advanced Neurological Centre; Sevilla Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Oliv\u00e9-Gadea","sequence":"additional","affiliation":[{"name":"Vall d\u2019Hebron University Hospital; Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Montoya","sequence":"additional","affiliation":[{"name":"Lluis Alcanyis Hospital; X\u00e1tiva Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Ruiz-Gim\u00e9nez","sequence":"additional","affiliation":[{"name":"Virgen de las Nieves University Hospital; Granada Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Zurita","sequence":"additional","affiliation":[{"name":"Infanta Leonor Hospital; Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the BRIVA-LIFE study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,12,27]]},"reference":[{"key":"10.1111\/ane.13059-BIB0001|ane13059-cit-0001","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.yebeh.2014.05.031","article-title":"The consequences of refractory epilepsy and its treatment","volume":"37","author":"Laxer","year":"2014","journal-title":"Epilepsy Behav"},{"key":"10.1111\/ane.13059-BIB0002|ane13059-cit-0002","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejphar.2011.04.064","article-title":"Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties","volume":"664","author":"Gillard","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1111\/ane.13059-BIB0003|ane13059-cit-0003","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/epi.13638","article-title":"Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein","volume":"58","author":"Wood","year":"2017","journal-title":"Epilepsia"},{"key":"10.1111\/ane.13059-BIB0004|ane13059-cit-0004","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1111\/epi.14532","article-title":"Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein","volume":"59","author":"Wood","year":"2018","journal-title":"Epilepsia"},{"key":"10.1111\/ane.13059-BIB0005|ane13059-cit-0005","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1111\/epi.13890","article-title":"Brivaracetam does not modulate ionotropic channels activated by glutamate, \u03b3-aminobutyric acid, and glycine in hippocampal neurons","volume":"58","author":"Niespodziany","year":"2017","journal-title":"Epilepsia"},{"key":"10.1111\/ane.13059-BIB0006|ane13059-cit-0006","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/epi.12433","article-title":"Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial","volume":"55","author":"Biton","year":"2014","journal-title":"Epilepsia"},{"key":"10.1111\/ane.13059-BIB0007|ane13059-cit-0007","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/epi.12432","article-title":"Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial","volume":"55","author":"Ryvlin","year":"2014","journal-title":"Epilepsia"},{"key":"10.1111\/ane.13059-BIB0008|ane13059-cit-0008","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1111\/epi.13212","article-title":"A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures","volume":"56","author":"Klein","year":"2015","journal-title":"Epilepsia"},{"key":"10.1111\/ane.13059-BIB0009|ane13059-cit-0009","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/epi.13768","article-title":"Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany","volume":"58","author":"Steinig","year":"2017","journal-title":"Epilepsia"},{"key":"10.1111\/ane.13059-BIB0010|ane13059-cit-0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.seizure.2017.03.010","article-title":"Real-life experience with brivaracetam in 101 patients with difficult-to-treat epilepsy-A monocenter survey","volume":"48","author":"Steinhoff","year":"2017","journal-title":"Seizure"},{"key":"10.1111\/ane.13059-BIB0011|ane13059-cit-0011","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fneur.2018.00038","article-title":"Brivaracetam in the Treatment of Patients with Epilepsy-First Clinical Experiences","volume":"9","author":"Zahnert","year":"2018","journal-title":"Front Neurol"},{"key":"10.1111\/ane.13059-BIB0012|ane13059-cit-0012","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/epi.14476","article-title":"Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus","volume":"59","author":"Strzelczyk","year":"2018","journal-title":"Epilepsia"},{"key":"10.1111\/ane.13059-BIB0013|ane13059-cit-0013","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3389\/fneur.2018.00569","article-title":"Efficacy, retention, and tolerability of brivaracetam in patients with epileptic encephalopathies: A Multicenter Cohort Study From Germany","volume":"9","author":"Willems","year":"2018","journal-title":"Front Neurol"},{"key":"10.1111\/ane.13059-BIB0014|ane13059-cit-0014","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.seizure.2018.07.017","article-title":"Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with Levetiracetam: A monocenter retrospective outcome analysis","volume":"61","author":"Hirsch","year":"2018","journal-title":"Seizure"},{"key":"10.1111\/ane.13059-BIB0015|ane13059-cit-0015","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"STROBE Initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"Elm","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1111\/ane.13059-BIB0016|ane13059-cit-0016","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1528-1157.1981.tb06159.x","article-title":"Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures","volume":"22","year":"1981","journal-title":"Epilepsia"},{"key":"10.1111\/ane.13059-BIB0017|ane13059-cit-0017","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"key":"10.1111\/ane.13059-BIB0018|ane13059-cit-0018","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/ane.12720","article-title":"EARLY-ESLI study: Long-term experience with eslicarbazepine acetate after first monotherapy failure","volume":"136","author":"Villanueva","year":"2017","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/ane.13059-BIB0019|ane13059-cit-0019","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1111\/epi.13224","article-title":"A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial-onset seizures in daily clinical practice: The VITOBA study","volume":"56","author":"Runge","year":"2015","journal-title":"Epilepsia"},{"key":"10.1111\/ane.13059-BIB0020|ane13059-cit-0020","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1212\/WNL.0000000000002864","article-title":"Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies","volume":"87","author":"Ben-Menachem","year":"2016","journal-title":"Neurology"},{"key":"10.1111\/ane.13059-BIB0021|ane13059-cit-0021","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s00415-017-8618-5","article-title":"Euro-Esli: a European audit of real-world use of eslicarbazepine acetate as a treatment for partial-onset seizures","volume":"264","author":"Villanueva","year":"2017","journal-title":"J Neurol"},{"key":"10.1111\/ane.13059-BIB0022|ane13059-cit-0022","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.yebeh.2017.04.006","article-title":"Retention of perampanel in adults with pharmacoresistant epilepsy at a single tertiary care center","volume":"73","author":"Wehner","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1111\/ane.13059-BIB0023|ane13059-cit-0023","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.yebeh.2011.11.026","article-title":"Rational polytherapy with lacosamide in clinical practice: results of a Spanish cohort analysis RELACOVA","volume":"23","author":"Villanueva","year":"2012","journal-title":"Epilepsy Behav"},{"key":"10.1111\/ane.13059-BIB0024|ane13059-cit-0024","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00228-017-2245-z","article-title":"Tolerability of new antiepileptic drugs: a network meta-analysis","volume":"73","author":"Zaccara","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/ane.13059-BIB0025|ane13059-cit-0025","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1212\/01.WNL.0000078031.32904.0D","article-title":"Psychiatric adverse events during levetiracetam therapy","volume":"61","author":"Mula","year":"2003","journal-title":"Neurology"},{"key":"10.1111\/ane.13059-BIB0026|ane13059-cit-0026","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1111\/j.1528-1167.2007.01262.x","article-title":"Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam","volume":"48","author":"Mula","year":"2007","journal-title":"Epilepsia"},{"key":"10.1111\/ane.13059-BIB0027|ane13059-cit-0027","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.yebeh.2015.09.005","article-title":"An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam","volume":"52","author":"Yates","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1111\/ane.13059-BIB0028|ane13059-cit-0028","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.seizure.2015.02.031","article-title":"Injuries from seizures are a serious, persistent problem in childhood onset epilepsy: a population-based study","volume":"27","author":"Camfield","year":"2015","journal-title":"Seizure"},{"key":"10.1111\/ane.13059-BIB0029|ane13059-cit-0029","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.pharep.2014.11.009","article-title":"Antiepileptic drugs and adverse skin reactions: An update","volume":"67","author":"B\u0142aszczyk","year":"2015","journal-title":"Pharmacol Rep"},{"key":"10.1111\/ane.13059-BIB0030|ane13059-cit-0030","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/jamaneurol.2014.808","article-title":"Effectiveness of antiepileptic drug combination therapy for partial-onset seizures based on mechanisms of action","volume":"71","author":"Margolis","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1111\/ane.13059-BIB0031|ane13059-cit-0031","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1528-1157.1997.tb01142.x","article-title":"Reappraisal of polytherapy in epilepsy: a critical review of drug load and adverse effects","volume":"38","author":"Deckers","year":"1997","journal-title":"Epilepsia"},{"key":"10.1111\/ane.13059-BIB0032|ane13059-cit-0032","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/ane.12943","article-title":"Behavioural changes in patients with intellectual disability treated with brivaracetam","volume":"138","author":"Andres","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/ane.13059-BIB0033|ane13059-cit-0033","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jamaneurol.2015.4515","article-title":"Efforts in epilepsy prevention in the last 40 Years: Lessons from a large nationwide study","volume":"73","author":"Sillanp\u00e4\u00e4","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1111\/ane.13059-BIB0034|ane13059-cit-0034","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1111\/bcp.13653","article-title":"New-onset epilepsy in the elderly","volume":"84","author":"Vu","year":"2018","journal-title":"Br J Clin Pharmacol"}],"container-title":["Acta Neurologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fane.13059","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ane.13059\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T23:03:45Z","timestamp":1720825425000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ane.13059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,27]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"URL":"https:\/\/doi.org\/10.1111\/ane.13059","archive":["Portico"],"relation":{},"ISSN":["0001-6314"],"issn-type":[{"value":"0001-6314","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12,27]]}}}